(Q39172020)

English

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit

scientific article published on 2 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit (English)

1 reference

Europe PubMed Central

9 September 2017

allosteric inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pierre Etienne Heudel

6

object named as

Pierre-Etienne Heudel

1 reference

Europe PubMed Central

9 September 2017

Isabelle Treilleux

9

object named as

Isabelle Treilleux

1 reference

Europe PubMed Central

9 September 2017

Thomas Bachelot

7

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

9 September 2017

author name string

Paul Vilquin

1

1 reference

Europe PubMed Central

9 September 2017

Marie Villedieu

2

1 reference

Europe PubMed Central

9 September 2017

Evelyne Grisard

3

1 reference

Europe PubMed Central

9 September 2017

Sabrina Ben Larbi

4

1 reference

Europe PubMed Central

9 September 2017

Sandra E Ghayad

5

1 reference

Europe PubMed Central

9 September 2017

Laura Corbo

8

1 reference

Europe PubMed Central

9 September 2017

Julie A Vendrell

10

1 reference

Europe PubMed Central

9 September 2017

Pascale A Cohen

11

1 reference

Europe PubMed Central

9 September 2017

language of work or name

0 references

publication date

2 May 2013

1 reference

Europe PubMed Central

9 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

9 September 2017

133

1 reference

Europe PubMed Central

9 September 2017

1589-1602

1 reference

Europe PubMed Central

9 September 2017

7

1 reference

Europe PubMed Central

9 September 2017

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Mechanisms of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Cracking the estrogen receptor's posttranslational code in breast tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Aromatase expression in ovarian epithelial cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Therapeutic implications of cancer stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Stem cells: their role in breast cancer development and resistance to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

The importance of distant metastases in hormone-sensitive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity i

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28182

21 January 2018

Identifiers

10.1002/IJC.28182

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39172020&oldid=1898845618"